Supply tensions in Téralithe LP 400 mg (lithium salt): recommendations to ensure the continuity of treatments

News Healthcare & Pharma Reports

Date: 16th May, 2025 Source: French National Agency for the Safety of Medicines and Health Products (ANSM) Country: France Original Source

Brief

On May 16, 2025, the French National Agency for the Safety of Medicines and Health Products (ANSM) issued an update regarding supply tensions in Téralithe LP 400 mg (lithium salt). The agency noted that supply tensions were caused by a conformity issue with the raw material used in the medication, exacerbated by increased demand, and expected to be resolved by June 2025 as scheduled deliveries are planned.

This content is restricted.

Highlights content goes here...

This content is restricted.

French National Agency for the Safety of Medicines and Health Products (ANSM)

RADA.AI

Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?

Suggested

Supply tensions in Téralithe LP 400 mg (lithium salt): recommendations to ensure the continuity of treatments

Brief

French National Agency for the Safety of Medicines and Health Products (ANSM)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.

Supply tensions in Téralithe LP 400 mg (lithium salt): recommendations to ensure the continuity of treatments

Brief

French National Agency for the Safety of Medicines and Health Products (ANSM)

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Verify OTP

Enter your Email

Verify Email

Tell us more about yourself

Select your work area

Select your country

All set.